Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?

As targeted molecular therapies and immuno-oncology have become pivotal in the management of patients with lung cancer, the essential requirement for high throughput analyses and clinical validation of biomarkers has become even more intense, with response rates maintained in the 20%–30% range. More...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofman, Paul, Badoual, Cécile, Henderson, Fiona, Berland, Léa, Hamila, Marame, Long-Mira, Elodie, Lassalle, Sandra, Roussel, Hélène, Hofman, Véronique, Tartour, Eric, Ilié, Marius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468415/
https://www.ncbi.nlm.nih.gov/pubmed/30818873
http://dx.doi.org/10.3390/cancers11030283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468415/
https://www.ncbi.nlm.nih.gov/pubmed/30818873
http://dx.doi.org/10.3390/cancers11030283

Ejemplares similares